AI-assisted biomarker segmentation offers precision in nAMD disease monitoring
Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.
CIME 2025 unveils a galaxy of innovation in modern eye care
Neda Shamie, MD, previews the May 4 conference, where a faculty of ophthalmologists and optometrists will explore the latest advancements and controversies.
50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
Celebrating a half-century of progress with Ophthalmology Times.
Companies announce presentations at upcoming 2025 ARVO Annual Meeting
The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.
BVI Medical receives 510(k) FDA clearance for glaucoma surgical system
Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.
ISO issues new standards for presbyopia-correcting IOL classification
Updated guidelines characterize IOLs by functional performance over optical design.
Effect of race on visual outcomes in DME treated with ranibizumab
The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.
FDA grants RMAT designation to Atsena Therapeutics' gene therapy for XLRS
ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.
Study finds knowledge gaps in public understanding of glaucoma and cataracts
A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.
Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and outlines his priorities for the year ahead as incoming ASCRS president.
Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US
This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.
Piecing it together: Does semaglutide fit the NAION puzzle?
Eyestem releases positive results from phase 1 trial in patients with geographic atrophy
Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.
Impact of social media intervention on follow-up for patients with congenital ectopia lentis
Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.
AI reading label system enhances retinal disease diagnosis and training in ophthalmology
In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.
Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform
The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.
Study finds geographic and institutional disparities for DR and DME clinical trials
Results showed an unequal distributions of these clinical trials among rural and low-income populations.
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy
VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).
Oculis completes enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for DME eye drop candidate
Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.
Pykus Therapeutics completes enrollment in trial evaluating PYK-2101
PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.
Harrow expands VEVYE Access for All program to Klarity-C patients
Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.
Opthea to lay off approximately 65% of company
The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.
Presbyopia treatment success begins with patient-centered care
Personalizing treatment options and setting realistic expectations are crucial.
Updated guidelines enhance choriocapillaris imaging in AMD with SS-OCTA
Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts
Novel multistage model enhances OCT GA segmentation
Researchers introduce a multistage dual-branch network to improve accuracy and efficiency
EMA application filed by Bayer to expand aflibercept 8 mg indication to include retinal vein occlusion
In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema
Relationship between fasting C-peptide and diabetic retinopathy in patients with type 2 diabetes mellitus
Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.
FDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD
A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.
